BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Filippas-Ntekouan S, Filippatos TD, Elisaf MS. SGLT2 inhibitors: are they safe? Postgrad Med. 2018;130:72-82. [PMID: 29039237 DOI: 10.1080/00325481.2018.1394152] [Cited by in Crossref: 38] [Cited by in F6Publishing: 33] [Article Influence: 7.6] [Reference Citation Analysis]
Number Citing Articles
1 Nakhal MM, Aburuz S, Sadek B, Akour A. Repurposing SGLT2 Inhibitors for Neurological Disorders: A Focus on the Autism Spectrum Disorder. Molecules 2022;27:7174. [DOI: 10.3390/molecules27217174] [Reference Citation Analysis]
2 Dagogo-Jack S, Cannon CP, Cherney DZI, Cosentino F, Liu J, Pong A, Gantz I, Frederich R, Mancuso JP, Pratley RE. Cardiorenal outcomes with ertugliflozin assessed according to baseline glucose-lowering agent: An analysis from VERTIS CV. Diabetes Obes Metab 2022;24:1245-54. [PMID: 35266296 DOI: 10.1111/dom.14691] [Reference Citation Analysis]
3 Carpentieri GB, Gonçalves SEAB, Casagrande MZ, Mourad WM, Pinto LGC, Zanella MT. SGLT2 Inhibition with Empagliflozin as a Possible Therapeutic Option for Postprandial Hypoglycemia After Bariatric Surgery. OBES SURG. [DOI: 10.1007/s11695-022-06119-4] [Reference Citation Analysis]
4 Chen S, Bian Y. circ_000166/miR-296 Aggravates the Process of Diabetic Renal Fibrosis by Regulating the SGLT2 Signaling Pathway in Renal Tubular Epithelial Cells. Disease Markers 2022;2022:1-10. [DOI: 10.1155/2022/6103086] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Alkabbani W, Zongo A, Minhas-Sandhu JK, Eurich DT, Shah BR, Alsabbagh MW, Gamble JM. Five comparative cohorts to assess the risk of genital tract infections associated with sodium-glucose cotransporter-2 inhibitors initiation in type 2 diabetes mellitus. Diabet Med 2022;:e14858. [PMID: 35460294 DOI: 10.1111/dme.14858] [Reference Citation Analysis]
6 Richardson B, Khan MQ, Brown SA, Watt KD, Izzy M. Personalizing Diabetes Management in Liver Transplant Recipients: The New Era for Optimizing Risk Management. Hepatol Commun 2021. [PMID: 34921530 DOI: 10.1002/hep4.1876] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Rokszin G, Kiss Z, Sütő G, Kempler P, Jermendy G, Fábián I, Szekanecz Z, Poór G, Wittmann I, Molnár GA. Sodium-Glucose Co-Transporter 2 Inhibitors May Change the Development of Urinary Tract and Hematological Malignancies as Compared With Dipeptidyl Peptidase-4 Inhibitors: Data of the Post-Hoc Analysis of a Nationwide Study. Front Oncol 2021;11:725465. [PMID: 34778040 DOI: 10.3389/fonc.2021.725465] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
8 Tsai KF, Chen YL, Chiou TT, Chu TH, Li LC, Ng HY, Lee WC, Lee CT. Emergence of SGLT2 Inhibitors as Powerful Antioxidants in Human Diseases. Antioxidants (Basel) 2021;10:1166. [PMID: 34439414 DOI: 10.3390/antiox10081166] [Cited by in Crossref: 12] [Cited by in F6Publishing: 15] [Article Influence: 12.0] [Reference Citation Analysis]
9 Chandrashekar M, Philip S, Nesbitt A, Joshi A, Perera M. Sodium glucose-linked transport protein 2 inhibitors: An overview of genitourinary and perioperative implications. Int J Urol 2021. [PMID: 34155680 DOI: 10.1111/iju.14624] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 Htet ZM, Karim M. Sodium-glucose co-transporter 2 inhibitors: game changers when handled with care? J R Soc Med 2021;114:351-8. [PMID: 33945350 DOI: 10.1177/01410768211011109] [Reference Citation Analysis]
11 Lingvay I, Greenberg M, Gallo S, Shi H, Liu J, Gantz I. Efficacy and safety of ertugliflozin in patients with type 2 diabetes mellitus and established cardiovascular disease using insulin: A VERTIS CV substudy. Diabetes Obes Metab 2021;23:1640-51. [PMID: 33769675 DOI: 10.1111/dom.14385] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
12 Şahin S, Haliloğlu Ö, Polat Korkmaz Ö, Durcan E, Rekalı Şahin H, Yumuk VD, Damcı T, İlkova HM, Oşar Siva Z. Does treatment with sodium-glucose co-transporter-2 inhibitors have an effect on sleep quality, quality of life, and anxiety levels in people with Type 2 diabetes mellitus? Turk J Med Sci 2020;51:735-42. [PMID: 33356033 DOI: 10.3906/sag-2008-37] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
13 Agra Montava I, Seres Roig M, Jodar Manzaneda V. [Diabetic euglycemic ketoacidosis, more iatrogeny?]. Semergen 2021;47:135-6. [PMID: 33055015 DOI: 10.1016/j.semerg.2020.07.005] [Reference Citation Analysis]
14 Ni L, Yuan C, Chen G, Zhang C, Wu X. SGLT2i: beyond the glucose-lowering effect. Cardiovasc Diabetol 2020;19:98. [PMID: 32590982 DOI: 10.1186/s12933-020-01071-y] [Cited by in Crossref: 44] [Cited by in F6Publishing: 48] [Article Influence: 22.0] [Reference Citation Analysis]
15 Lee IH, Ahn DJ. Dapagliflozin-associated euglycemic diabetic ketoacidosis in a patient with type 2 diabetes mellitus: A case report. Medicine (Baltimore) 2020;99:e20228. [PMID: 32481295 DOI: 10.1097/MD.0000000000020228] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]
16 Jensen MH, Dethlefsen C, Hejlesen O, Vestergaard P. Association of severe hypoglycemia with mortality for people with diabetes mellitus during a 20-year follow-up in Denmark: a cohort study. Acta Diabetol 2020;57:549-58. [PMID: 31754819 DOI: 10.1007/s00592-019-01447-x] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 7.0] [Reference Citation Analysis]
17 Ersoy C. SGLT 2 inhibitors: Antidiabetic agents with promising effects beyond glucose control. Turkish Journal of Internal Medicine 2020;2:1-4. [DOI: 10.46310/tjim.674514] [Reference Citation Analysis]
18 Bolevich SS, Litvitsky PF, Jakovljevic V, Bolevich SB. Long-term use of dipeptyl peptidase-4 inhibitors suppresses systemic oxidative stress in rats with type 2 diabetes. jour 2019;10:21-30. [DOI: 10.47093/22187332.2019.4.21-30] [Reference Citation Analysis]
19 McGill JB, Subramanian S. Safety of Sodium-Glucose Co-Transporter 2 Inhibitors. Am J Cardiol 2019;124 Suppl 1:S45-52. [PMID: 31741440 DOI: 10.1016/j.amjcard.2019.10.029] [Cited by in Crossref: 26] [Cited by in F6Publishing: 32] [Article Influence: 8.7] [Reference Citation Analysis]
20 Yaribeygi H, Sathyapalan T, Maleki M, Jamialahmadi T, Sahebkar A. Molecular mechanisms by which SGLT2 inhibitors can induce insulin sensitivity in diabetic milieu: A mechanistic review. Life Sci 2020;240:117090. [PMID: 31765648 DOI: 10.1016/j.lfs.2019.117090] [Cited by in Crossref: 30] [Cited by in F6Publishing: 32] [Article Influence: 10.0] [Reference Citation Analysis]
21 Berstein LM. Is cancer incidence modified by SGLT2 inhibitors? Diabetes mellitus 2019;22:399-402. [DOI: 10.14341/dm10119] [Reference Citation Analysis]
22 Çadırcı K, Özdemir Tozlu Ö, Türkez H. The in vitro cytotoxicity, genotoxicity and oxidative damage potential of dapagliflozin, on cultured human blood cells. Turkish Journal of Biochemistry 2019;44:692-698. [DOI: 10.1515/tjb-2019-0111] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
23 Baruah MP, Kalra S. Comparative Efficacy and Safety Among Sodium-glucose Cotransporter-2 Inhibitors in Type 2 Diabetes - Results from a Retrospective Single-centre Study. Eur Endocrinol 2019;15:113-8. [PMID: 31616503 DOI: 10.17925/EE.2019.15.2.113] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
24 Fu H, Liu S, Bastacky SI, Wang X, Tian XJ, Zhou D. Diabetic kidney diseases revisited: A new perspective for a new era. Mol Metab. 2019;30:250-263. [PMID: 31767176 DOI: 10.1016/j.molmet.2019.10.005] [Cited by in Crossref: 68] [Cited by in F6Publishing: 59] [Article Influence: 22.7] [Reference Citation Analysis]
25 Kashiwagi A, Shestakova MV, Ito Y, Noguchi M, Wilpshaar W, Yoshida S, Wilding JPH. Safety of Ipragliflozin in Patients with Type 2 Diabetes Mellitus: Pooled Analysis of Phase II/III/IV Clinical Trials. Diabetes Ther 2019;10:2201-17. [PMID: 31606880 DOI: 10.1007/s13300-019-00699-8] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 2.3] [Reference Citation Analysis]
26 Shah PA, Shrivastav PS, Sharma V, Yadav MS. Challenges in simultaneous extraction and chromatographic separation of metformin and three SGLT-2 inhibitors in human plasma using LC–MS/MS. Journal of Pharmaceutical and Biomedical Analysis 2019;175:112790. [DOI: 10.1016/j.jpba.2019.112790] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
27 Papakitsou I, Vougiouklakis G, Elisaf MS, Filippatos TD. Differential pharmacology and clinical utility of dapagliflozin in type 2 diabetes. Clin Pharmacol 2019;11:133-43. [PMID: 31572020 DOI: 10.2147/CPAA.S172353] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
28 Dokmak A, Almeqdadi M, Trivedi H, Krishnan S. Rise of sodium-glucose cotransporter 2 inhibitors in the management of nonalcoholic fatty liver disease. World J Hepatol 2019; 11(7): 562-573 [PMID: 31388398 DOI: 10.4254/wjh.v11.i7.562] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
29 Bhuiyan MMR, Begum A. Promise, peril, and possible new treatment options incurred by sodium glucose co-transporter 2 (SGLT2) inhibitors: A precise review up to 2018. Obesity Medicine 2019;14:100099. [DOI: 10.1016/j.obmed.2019.100099] [Reference Citation Analysis]
30 Scheen AJ. An update on the safety of SGLT2 inhibitors. Expert Opin Drug Saf 2019;18:295-311. [PMID: 30933547 DOI: 10.1080/14740338.2019.1602116] [Cited by in Crossref: 82] [Cited by in F6Publishing: 66] [Article Influence: 27.3] [Reference Citation Analysis]
31 Filippatos TD, Liontos A, Papakitsou I, Elisaf MS. SGLT2 inhibitors and cardioprotection: a matter of debate and multiple hypotheses. Postgrad Med. 2019;131:82-88. [PMID: 30757937 DOI: 10.1080/00325481.2019.1581971] [Cited by in Crossref: 49] [Cited by in F6Publishing: 37] [Article Influence: 16.3] [Reference Citation Analysis]
32 Keresztes P, Peacock-johnson A. CE: Type 2 Diabetes: A Pharmacologic Update. AJN, American Journal of Nursing 2019;119:32-40. [DOI: 10.1097/01.naj.0000554008.77013.cf] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
33 Inouye BM, Hughes FM Jr, Jin H, Lütolf R, Potnis KC, Routh JC, Rouse DC, Foo WC, Purves JT. Diabetic bladder dysfunction is associated with bladder inflammation triggered through hyperglycemia, not polyuria. Res Rep Urol 2018;10:219-25. [PMID: 30533402 DOI: 10.2147/RRU.S177633] [Cited by in Crossref: 5] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
34 Filippas-ntekouan S, Tsimihodimos V, Filippatos T, Dimitriou T, Elisaf M. SGLT-2 inhibitors: pharmacokinetics characteristics and effects on lipids. Expert Opinion on Drug Metabolism & Toxicology 2018. [DOI: 10.1080/17425255.2018.1541348] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 3.3] [Reference Citation Analysis]
35 Hu J, Deng A, Zhao Y. Ertugliflozin as a monotherapy for the treatment of type 2 diabetes. Expert Opinion on Pharmacotherapy 2018;19:1841-7. [DOI: 10.1080/14656566.2018.1525360] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
36 Raschi E, Poluzzi E, Fadini GP, Marchesini G, De Ponti F. Observational research on sodium glucose co-transporter-2 inhibitors: A real breakthrough? Diabetes Obes Metab 2018;20:2711-23. [PMID: 30003655 DOI: 10.1111/dom.13468] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 3.5] [Reference Citation Analysis]
37 Tsimihodimos V, Filippatos TD, Elisaf MS. SGLT2 inhibitors and the kidney: Effects and mechanisms. Diabetes Metab Syndr 2018;12:1117-23. [PMID: 29909004 DOI: 10.1016/j.dsx.2018.06.003] [Cited by in Crossref: 27] [Cited by in F6Publishing: 30] [Article Influence: 6.8] [Reference Citation Analysis]
38 Scheen AJ. GLP-1 receptor agonists and cardiovascular protection: A class effect or not? Diabetes & Metabolism 2018;44:193-6. [DOI: 10.1016/j.diabet.2017.12.009] [Cited by in Crossref: 19] [Cited by in F6Publishing: 21] [Article Influence: 4.8] [Reference Citation Analysis]
39 Rehman K, Saeed K, Munawar SM, Akash MSH. Resveratrol regulates hyperglycemia-induced modulations in experimental diabetic animal model. Biomedicine & Pharmacotherapy 2018;102:140-6. [DOI: 10.1016/j.biopha.2018.03.050] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 5.8] [Reference Citation Analysis]
40 Scheen A. Place des inhibiteurs des SGLT2 dans le traitement du patient diabétique de type 2. Médecine des Maladies Métaboliques 2018;12:22-30. [DOI: 10.1016/s1957-2557(18)30005-1] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]